Publications by authors named "Nilubol Raunroadroong"
Article Synopsis
- This study compares the clinical effectiveness of a chemotherapy treatment (FOLFOX) to a multikinase inhibitor (Sorafenib) for advanced hepatocellular carcinoma (aHCC) in real-life scenarios, especially in resource-limited settings.
- An analysis of 504 patients from Thai hospitals found that Sorafenib provided a median overall survival of 11.38 months, while FOLFOX resulted in 8.22 months, indicating that FOLFOX had significantly shorter overall survival and progression-free survival.
- Despite the shorter survival rates, FOLFOX still offers a potential treatment option for aHCC, extending overall survival and providing alternative therapy for patients in developing countries.
Efficacy and tolerability of BP-C1 in metastatic breast cancer: a Phase II, randomized, double-blind, and placebo-controlled Thai multi-center study.
Kritiya Butthongkomvong Nilubol Raunroadroong Sirikul Sorrarichingchai Isaraporn Sangsaikae Vichien Srimuninnimit
Breast Cancer (Dove Med Press)
January 2019
Aims: The aim of this study was to compare the efficacy and tolerability of BP-C1 vs equal-looking placebo in metastatic breast cancer.
Materials And Methods: A randomized, double-blind, placebo-controlled multi-center study with a semicross-over design was performed. Sixteen patients received daily intramuscular injection of 0.
Aim: Cholangiocarcinoma (CCA) is a common form of cancer in Thailand. The diagnosis of CCA by pathology is widely accepted. Unfortunately, tissue diagnosis of mass-forming intrahepatic cholangiocarcinoma is difficult to perform due to the risk of the procedure and accessibility.
View Article and Find Full Text PDF